CO.DON AG: CO.DON nominated by US magazine 'MedTech Outlook' for 'TOP 10 Orthopedic Solution Providers in Europe 2019'

DGAP-News: CO.DON AG / Key word(s): Miscellaneous CO.DON AG: CO.DON nominated by US magazine 'MedTech Outlook' for 'TOP 10 Orthopedic Solution Providers in Europe 2019' 21.11.2019 / 10:00 The issuer is solely responsible for the content of this announcement. CO.DON nominated by US magazine "MedTech Outlook" for "TOP 10 Orthopedic Solution Providers in Europe 2019" Berlin/Teltow, 21 November 2019 - CO.DON AG has been nominated in the November issue of MedTech Outlook magazine for the "TOP 10 Orthopedic Solution Providers in Europe - 2019", making it one of the ten leading companies in Europe in terms of its advanced and innovative solutions for orthopaedic applications. For this annual award the editors of MedTech Outlook magazine evaluate some of the best-known European companies in the industry, shortlisting those who stand out in their sector for their development and application of the latest technological trends. CO.DON is one of the leading specialists in cell cultivation and produces autologous cell therapies for the regenerative treatment of articular cartilage defects. MedTech Outlook is a branch leading print magazine based in California, which tracks and reports on the trends, challenges and latest solutions in global medical technology. It offers decision-makers and experts a platform for sharing their views on new developments that are impacting health care. Link to the article: https://orthopedic-europe.medicaltechoutlook.com/vendor/codon-an-alternative-approach-to-treating-cartilage-defects-cid-526-mid-54.html CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 14,500 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product from the European Medicines Agency (EMA). The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs (Spokesman), Tilmann Bur (COO). Further information is available from www.codon.de.   Investor Relations and Press Contact Matthias Meißner Director Corporate Communications / Investor Relations / Public Relations Tel. [phone] Fax [phone] Email: [e-mail]   21.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:	English
Company:	CO.DON AG
	Warthestraße 21
	14513 Teltow
	Germany
Phone:	03328 43460
Fax:	03328 434643
E-mail:	[e-mail]
Internet:	www.codon.de
ISIN:	DE000A1K0227
WKN:	A1K022
Listed:	Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID:	918421

End of News	DGAP News Service

918421  21.11.2019